

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

NCT04202341

Status	RECRUITING
Sponsor	Alexion Pharmaceuticals, Inc.
Enrollment	500 participants

Key Eligibility Criteria

Inclusion (3)

- Participants with a diagnosis of gMG who are treated with Alexion C5IT at the time of enrollment, including patients previously treated with Soliris or Ultomiris and withdrawn from treatment.
- Capable of giving signed informed consent, which includes compliance with the protocol requirements and restrictions.
- Participants must have myasthenia gravis historical data, such as MG-ADL and MGFA class, available to be enrolled in the Registry.

Exclusion (1)

- \. Participants currently enrolled in an Alexion-sponsored interventional clinical study for treatment of gMG cannot be enrolled in the Alexion gMG Registry while enrolled/participating in the clinical study for gMG therapy.

Locations (51 total)

Clinical Trial Site, Birmingham, Alabama, United States
Clinical Trial Site, Scottsdale, Arizona, United States
Clinical Trial Site, Fresno, California, United States
... and 48 more locations